Biohaven (BHVN) EBT (2021 - 2026)

Biohaven has disclosed EBT across 6 years of filings, most recently posting -$130.3 million for Q1 2026.

• EBT for Q1 2026 came in at -$130.3 million, up 41.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$646.6 million (up 27.17% YoY), and the FY2025 annual result was -$737.4 million, up 12.81% from the prior year.
• EBT came in at -$130.3 million for Q1 2026 at Biohaven, up from -$145.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$67.6 million in Q3 2022 to a low of -$319.6 million in Q2 2024.
• The 5-year median for EBT is -$160.4 million (2024), against an average of -$158.4 million.
• Across the five-year window, EBT slumped 335.47% in 2022 and soared 55.28% in 2023, its largest moves.
• Biohaven's EBT stood at -$215.2 million in 2022, then jumped by 32.19% to -$146.0 million in 2023, then fell by 27.97% to -$186.8 million in 2024, then climbed by 22.27% to -$145.2 million in 2025, then grew by 10.29% to -$130.3 million in 2026.
• The last three EBT figures came in at -$130.3 million (Q1 2026), -$145.2 million (Q4 2025), and -$173.2 million (Q3 2025), per Business Quant data.